ESR1 and breast cancer: In turn, PRDM1/BLIMP1 downregulates ERα gene expression by direct binding to its promoter, thus promoting a reduction in the levels of E-cadherin and γ-catenin and a corresponding increase in migratory phenotype of breast cancer cells (Figure 1A) [37].